These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15813090)

  • 1. [Randomized Aldactone Evaluation Study (RALES)].
    Uchida K; Nakano S; Kigoshi T
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():330-5. PubMed ID: 15813090
    [No Abstract]   [Full Text] [Related]  

  • 2. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's old is new again. Spironolactone and heart failure.
    Lock M; Chun R
    Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone antagonists in congestive heart failure.
    Soberman J; Chafin CC; Weber KT
    Curr Opin Investig Drugs; 2002 Jul; 3(7):1024-8. PubMed ID: 12186262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
    Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
    Opasich C
    Ital Heart J Suppl; 2000 Mar; 1(3):425-6. PubMed ID: 10815276
    [No Abstract]   [Full Text] [Related]  

  • 13. Aldosterone and spironolactone in heart failure.
    Weber KT
    N Engl J Med; 1999 Sep; 341(10):753-5. PubMed ID: 10471464
    [No Abstract]   [Full Text] [Related]  

  • 14. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of spironolactone in heart failure should be emphasised.
    Mapstone J; Houston B; Gogarty M
    BMJ; 2000 Sep; 321(7262):706-7. PubMed ID: 11202944
    [No Abstract]   [Full Text] [Related]  

  • 17. [New evidence for the usefulness of an old drug in the treatment of heart failure].
    Oseguera Moguel J
    Rev Invest Clin; 2000; 52(1):14-6. PubMed ID: 10818804
    [No Abstract]   [Full Text] [Related]  

  • 18. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone for heart failure: a worthy addition to therapy.
    Rittenhouse SK
    Adv Nurse Pract; 2001 Jan; 9(1):34-6, 39. PubMed ID: 12416036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.